Janet Woodcock to Serve as Acting Commissioner of FDA
Woodcock will serve as acting commissioner of FDA, taking over for Stephen Hahn, FDA’s previous acting commissioner.
On Jan. 20, 2021, Janet Woodcock, MD announced in a note to FDA staff members that she will serve as acting commissioner of FDA, taking over for Stephen Hahn, FDA’s previous acting commissioner.
Woodcock joined FDA in 1986 and has held several positions, including deputy commissioner and chief medical officer, deputy commissioner for operations, chief operating officer for the commissioner’s office, and director of the Center for Drug Evaluation and Research (CDER).
“I know you all have endured hardships while carrying out our public health mission, balancing work and family, and trying to stay safe. It has not gone unnoticed,” she wrote in her note. “I believe life will improve in 2021, but I don’t know how quickly that will happen. The hope keeps me going. I look forward to working with you to achieve our vital public health mission, and with our HHS [Department of Health and Human Services] partners and The White House during this transitional period.”
Source: FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
